Healthcare Royalty, Inc. (HCRX)

Healthcare Royalty was planning to go public, but the IPO has been withdrawn.
IPO Price Range
$15.00 - $17.00
Shares Offered
46,875,000
Deal Size
$750.00M

Company Description

Healthcare Royalty is the leading mid-market royalty acquisition company, based upon the number of transactions and aggregate value of capital deployed since 2016.

We focus on growth assets and emerging companies driving innovation in the biopharmaceutical industry. Our mission is to facilitate innovation by deploying capital consistently and reliably in products that serve unmet or underserved medical needs.

We intend to achieve this mission by expanding our portfolio of approved and pre-approval products using cash flow generated by our existing portfolio as well as capital raised in the public equity market and debt raised in the public and private markets.

We have purposefully built a diverse portfolio across the therapeutic spectrum, including blockbuster assets such as Shingrix, innovative growth products such as Krystexxa, and recently launched products such as Xpovio.

Our process for evaluating acquisition and financing opportunities has been optimized through decades of experience and is designed to efficiently assess opportunities, identify risks and establish appropriate Royalty-Related Transaction structures.

Healthcare Royalty, Inc.
Country United States
Founded 2006
Industry Biotechnology
Sector Health Care
Employees 25
CEO Clarke B. Futch

Contact Details

Address:
300 Atlantic St, Suite 600
Stamford, CT 06901
United States
Phone (203) 487-8300
Website healthcareroyalty.com

Stock Details

Ticker Symbol HCRX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency US Dollars
CIK Code 1859651

Key Executives

Name Position
Clarke B. Futch Chairman and Chief Executive Officer
Christopher A. White President and Chief Financial Officer
Timothy R.M. Bryant General Counsel
Thomas K. Conner Chief Accounting Officer and Treasurer
Carlos M. Almodóvar Chief Business Officer